

SUMMARY

In one aspect, there is provided a process for preparing a compound of Formula A:




A

or a pharmaceutically acceptable salt thereof, wherein either R_1 or R_2 is independently Cl, F, $-CF_3$, or $-CH_3$, and the other is H; and R_7 is H or PG, wherein the process comprises reacting a compound of structure 8:



8

or a salt thereof, wherein R_7 is PG or H; wherein PG is an alcohol protecting group, in a solvent with an amine of structure 9



9,

or a salt thereof, and a reducing agent. Suitable reducing reagents are disclosed elsewhere, in this application.

Intermediates useful in preparing the compounds of Formula A are also disclosed herein.

of at least 98 % area containing less than 1 % area of one or more dihydroquinoline or quinoline based impurities.

In another aspect, there is provided a compound that is (R)-2-(4-(2-hydroxy-8-(trifluoromethyl)-5H-chromeno[4,3-c]quinolin-5-yl)phenoxy)ethane-1,1-diol or a salt thereof.

Also disclosed herein is a process for preparing pyridine borane, the process comprising: reacting a pyridinium salt and sodium borohydride in a solvent.

BRIEF DESCRIPTION OF THE FIGURES

FIG 1 is chromatography overlay of Preparation 18b, Preparation 19, and Alternate Preparation 19 utilizing chromatography system 1.


FIG 2 is expanded version of Figure 1.

FIG 3 is chromatography overlay of Preparation 18b, Preparation 19, and Alternate Preparation 19 utilizing chromatography system 2.

DETAILED DESCRIPTION

Several methods of preparing the compound of Formula A are described herein. While these methods change the order in which a group or portion of the molecule is added to the quinoline core or otherwise manipulated, each method utilizes the reaction between structures 8 and 9. As described below, the Compounds of Formula A contain a chiral center, and the methods described herein may be useful in the preparation of enantio-enriched material.


Compounds of Formula A contain a chiral center and the methods described herein can be used to prepare racemic Formula A or enantio-enriched Formula A that comprises predominantly the R enantiomer or the S enantiomer. The R and S enantiomers encompassed by Formula A are shown immediately below. The R-enantiomeric form is exemplified in Formula B:



B,


CLAIMS

1. A process for preparing a compound of Formula A:




A

or a pharmaceutically acceptable salt thereof, wherein either R_1 or R_2 is independently Cl, F, $-CF_3$, or $-CH_3$, and the other is H; and R_7 is H or PG, wherein the process comprises reacting a compound of structure **8**:



8

or a salt thereof, wherein R_7 is PG or H; wherein PG is an alcohol protecting group, in a solvent with an amine of structure **9**




9,

or a salt thereof, and a reducing agent.

2. The process of claim 1, wherein the reducing agent is STAB, $LiBH_4$, $NaBH_4$, $NaBH_3CN$ or pyridine borane.

3. The process of claim 1, comprising preparing a compound of structure **8**, or a salt thereof, the process comprising reacting a compound of structure **7**




7

with an acid, wherein each R_5 is independently C_1-C_6 alkyl or the two R_5 groups combined are -CH_2CH_2- or -$CH_2CH_2CH_2$-.

4. The process of claim 3, wherein the acid comprises HCl, H_2SO_4, *p*-TsOH, methanesulfonic acid, trifluoromethanesulfonic acid, acetic acid, or trichloroacetic acid.

5. The process of claim 3, wherein the reaction is performed in a solvent and the solvent comprises water.

6. The process according to claim 3, comprising preparing a compound of structure **7**, or a salt thereof, the process comprising reacting a compound of structure **6**




6

with a base.

7. The process of claim 6, wherein the base comprises Cs_2CO_3, NaH, sodium *tert*-butoxide, NaOH, LiOH, KOH, sodium *tert*-pentoxide, potassium *tert*-pentoxide, or DBU.

8. The process according to claim 6, comprising preparing a compound of structure **6**, or a salt thereof, the process comprising reacting a compound of structure 4




4

with a reducing agent.

9. The process according to claim 8, wherein the ketone reducing agent comprises $LiAlH_4$, $NaBH_4$, or borane-ligand, where the ligand is THF, Me_2S, catechol, or N,N-diethylaniline.


10. The process according to claim 8, comprising preparing a compound of structure **4**, or salt thereof, the process comprising reacting a compound of structure 3



3


with $HOCH_2CH(OR_5)_2$.

11. The process according to claim 10, comprising preparing a compound of structure **3**, or salt thereof, the process comprising a cross-coupling reaction between a compound of structure **1**



1

and a compound of structure **2**




2

wherein R_6 can be hydrogen or alkyl or a structure where the two R_6 groups are joined by at least two carbons, to form dioxaborolanes or dioxaborinanes, in the presence of a catalyst.

12. The process of claim 11, wherein the catalyst comprises a transition metal catalyst.


13. The process of claim 12, wherein the transition metal catalyst comprises a Pd catalyst.

14. The process according to claim 1, wherein the compound of structure 8 is the compound of structure **8B**:




8B.

15. The process according to claim 3, wherein the compound of structure 7 is the compound of structure **7B**:




7B.

16. The process according to claim 6, wherein the compound of structure 6 is the compound of structure **6B**:



6B.


17. The process according to claim 1, wherein the compound of Formula A or the pharmaceutically acceptable salt thereof is a compound of Formula B





B


or a pharmaceutically acceptable salt thereof, wherein either R_1 or R_2 is independently Cl, F, $-CF_3$, or $-CH_3$, and the other is H; and R_7 is H or PG.


18. The process of claim 1, wherein the compound, or the pharmaceutically acceptable salt thereof, is selected from:


















and



.

19. The process of claim 18, wherein the compound is provided as the tosylate salt.

20. A compound that is (R)-2-(4-(2-hydroxy-8-(trifluoromethyl)-5H-chromeno[4,3-c]quinolin-5-yl)phenoxy)ethane-1,1-diol or a salt thereof.